Alumis' Envudeucitinib Shows Promise in Treating Plaque Psoriasis with Rapid Improvements in Skin Clearance and Quality of Life.

Alumis' envudeucitinib has demonstrated early and robust improvements in skin clearance, quality of life, and psoriasis symptoms in two Phase 3 trials. The oral tyrosine kinase 2 inhibitor achieved high PASI 90 and PASI 100 responses by Week 16, with significant continued improvements by Week 24. Envudeucitinib also showed a favorable safety and tolerability profile, consistent with the Phase 2 program. The results were presented at the 2026 American Academy of Dermatology Annual Meeting.